SCHEMBL6987717

SCHEMBL6987717

N#CCCc1ccc(C(=O)O)cc1Br

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 1/20 0.39
AGTR1 P30556 1/20 0.39
AGTR2 P50052 1/20 0.39
FFAR1 O14842 1/20 0.36
FFAR4 Q5NUL3 1/20 0.36
KDM5A P29375 1/20 0.35
KDM5B Q9UGL1 1/20 0.35
KDM4E B2RXH2 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
POLB P06746 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
CA4 P22748 1/20 0.35
CA6 P23280 1/20 0.35
PTGS2 P35354 1/20 0.35
CA7 P43166 1/20 0.35
CA9 Q16790 1/20 0.35
CA14 Q9ULX7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28051580 0.80 TTR (0.44) TTRAGTR1AGTR2KDM4ECA12
SCHEMBL27825582 0.80 TTR (0.44) TTRAGTR1AGTR2KDM4ECA12
SCHEMBL11509525 0.78 AGTR1 (0.49) TTRAGTR1AGTR2KDM4EGAA
SCHEMBL9643977 0.78 TTR (0.42) TTRAGTR1AGTR2KDM4ECA12
SCHEMBL1174421 0.75 ACE2 (0.49) TTRAGTR1AGTR2KDM4ECA12
SCHEMBL29793345 0.75 ACE2 (0.49) TTRAGTR1AGTR2KDM4ECA12
SCHEMBL3576069 0.75 ALDH1A1 (0.50) TTRAGTR1AGTR2KDM4ECA12
SCHEMBL928246 0.75 TTR (0.47) TTRAGTR1AGTR2KDM4ECA12
SCHEMBL105114 0.74 TTR (0.45) TTRAGTR1AGTR2KDM4ECA12
SCHEMBL11015995 0.74 TTR (0.45) TTRAGTR1AGTR2KDM4ECA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1276726-A2 SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS Abbott Laboratories (US) 2003-01-22 EP disclosed
US-20020019527-A1 Substituted phenyl farnesyltransferase inhibitors ABBOTT LABORATORIES 2002-02-14 US disclosed
WO-2001081316-A2 SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS ABBOTT LABORATORIES (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019527-A1 Substituted phenyl farnesyltransferase inhibitors FNTA, FNTB, SLC10A1 TTR 651/4885AGTR1 662/4885AGTR2 1136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.